Oral Oncology
Volume 45, Issue 1 , Pages 2-9 , January 2009

t(11;19) translocation and CRTC1-MAML2 fusion oncogene in mucoepidermoid carcinoma

Received 20 December 2007 ,Revised 6 March 2008 ,Accepted 7 March 2008.

References 

  1. Speight PM, Barrett AW. Salivary gland tumours. Oral Dis. 2002;8(5):229–240
  2. Jones AV, Craig GT, Speight PM, Franklin CD. The range and demographics of salivary gland tumours diagnosed in a UK population. Oral Oncol. 2007;44(4):407–417
  3. Granata C, Battistini E, Toma P, Balducci T, Mattioli G, Fregonese B, et al. Mucoepidermoid carcinoma of the bronchus: a case report and review of the literature. Pediatr Pulmonol. 1997;23(3):226–232
  4. Heitmiller RF, Mathisen DJ, Ferry JA, Mark EJ, Grillo HC. Mucoepidermoid lung tumors. Ann Thorac Surg. 1989;47(3):394–399
  5. Yousem SA, Hochholzer L. Mucoepidermoid tumors of the lung. Cancer. 1987;60(6):1346–1352
  6. Baloch ZW, Solomon AC, LiVolsi VA. Primary mucoepidermoid carcinoma and sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: a report of nine cases. Mod Pathol. 2000;13(7):802–807
  7. Bhandarkar ND, Chan J, Strome M. A rare case of mucoepidermoid carcinoma of the thyroid. Am J Otolaryngol. 2005;26(2):138–141
  8. Di Tommaso L, Foschini MP, Ragazzini T, Magrini E, Fornelli A, Ellis IO, et al. Mucoepidermoid carcinoma of the breast. Virchows Arch. 2004;444(1):13–19
  9. Sofinski SJ, Brown BJ, Rao N, Wan WL. Mucoepidermoid carcinoma of the lacrimal gland. Case report and review of the literature. Ophthal Plast Reconstr Surg. 1986;2(3):147–151
  10. Robinson JW, Brownstein S, Jordan DR, Hodge WG. Conjunctival mucoepidermoid carcinoma in a patient with ocular cicatricial pemphigoid and a review of the literature. Surv Ophthalmol. 2006;51(5):513–519
  11. Pinkston JA, Cole P. Incidence rates of salivary gland tumors: results from a population-based study. Otolaryngol Head Neck Surg. 1999;120(6):834–840
  12. National Cancer Institute. SEER cancer statistics review 1975–2004. http.//seer.cancer.gov/csr/1975_2004/results_merged/sect_20_oral_cavity [accessed 23.11.2007].
  13. Ostman J, Anneroth G, Gustafsson H, Tavelin B. Malignant salivary gland tumours in Sweden 1960–1989 – an epidemiological study. Oral Oncol. 1997;33(3):169–176
  14. Bhattacharyya N, Fried MP. Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol. 2005;26(1):39–44
  15. Pires FR, Pringle GA, de Almeida OP, Chen SY. Intra-oral minor salivary gland tumors: a clinicopathological study of 546 cases. Oral Oncol. 2007;43(5):463–470
  16. Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB. Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer. 2005;103(12):2544–2550
  17. Saku T, Hayashi Y, Takahara O, Matsuura H, Tokunaga M, Tokunaga M, et al. Salivary gland tumors among atomic bomb survivors, 1950–1987. Cancer. 1997;79(8):1465–1475
  18. Modan B, Chetrit A, Alfandary E, Tamir A, Lusky A, Wolf M, et al. Increased risk of salivary gland tumors after low-dose irradiation. Laryngoscope. 1998;108(7):1095–1097
  19. Whatley WS, Thompson JW, Rao B. Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg. 2006;134(3):385–388
  20. Stenman G. Fusion oncogenes and tumor type specificity – insights from salivary gland tumors. Semin Cancer Biol. 2005;15(3):224–235
  21. Tonon G, Modi S, Wu L, Kubo A, Coxon AB, Komiya T, et al. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet. 2003;33(2):208–213
  22. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7(4):233–245
  23. Xia SJ, Barr FG. Chromosome translocations in sarcomas and the emergence of oncogenic transcription factors. Eur J Cancer. 2005;41(16):2513–2527
  24. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Evidence of recurrent gene fusions in common epithelial tumors. Trends Mol Med. 2006;12(11):529–536
  25. Hibbard MK, Kozakewich HP, Dal Cin P, Sciot R, Tan X, Xiao X, et al. PLAG fusion oncogenes in lipoblastoma. Cancer Res. 2000;60(17):4869–4872
  26. Enlund F, Behboudi A, Andren Y, Oberg C, Lendahl U, Mark J, et al. Altered Notch signaling resulting from expression of a WAMTP1-MAML2 gene fusion in mucoepidermoid carcinomas and benign Warthin’s tumors. Exp Cell Res. 2004;292(1):21–28
  27. Martins C, Cavaco B, Tonon G, Kaye FJ, Soares J, Fonseca I. A study of MECT1-MAML2 in mucoepidermoid carcinoma and Warthin’s tumor of salivary glands. J Mol Diagn. 2004;6(3):205–210
  28. Behboudi A, Enlund F, Winnes M, Andren Y, Nordkvist A, Leivo I, et al. Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene. Genes Chromosomes Cancer. 2006;45(5):470–481
  29. Okabe M, Miyabe S, Nagatsuka H, Terada A, Hanai N, Yokoi M, et al. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin Cancer Res. 2006;12(13):3902–3907
  30. Tirado Y, Williams MD, Hanna EY, Kaye FJ, Batsakis JG, El-Naggar AK. CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin’s tumors: implications for histogenesis and biologic behavior. Genes Chromosomes Cancer. 2007;46(7):708–715
  31. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol. 2001;2(8):599–609
  32. Wu L, Liu J, Gao P, Nakamura M, Cao Y, Shen H, et al. Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation. EMBO J. 2005;24(13):2391–2402
  33. Miele L. Notch signaling. Clin Cancer Res. 2006;12(4):1074–1079
  34. Komiya T, Park Y, Modi S, Coxon AB, Oh H, Kaye FJ. Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation. Oncogene. 2005;25(45):6128–6132
  35. Conkright MD, Canattieri G, Screaton R, Guzman E, Miraglia L, Hogenesch JB, et al. TORCs: transducers of regulated CREB activity. Mol Cell. 2003;12(2):413–423
  36. Coxon A, Rozenblum E, Park YS, Joshi N, Tsurutani J, Dennis PA, et al. Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. Cancer Res. 2005;65(16):7137–7144
  37. Nordkvist A, Gustafsson H, Juberg-Ode M, Stenman G. Recurrent rearrangements of 11q14–22 in mucoepidermoid carcinoma. Cancer Genet Cytogenet. 1994;74(2):77–83
  38. Horsman DE, Berean K, Durham JS. Translocation (11;19)(q21;p13 1) in mucoepidermoid carcinoma of salivary gland. Cancer Genet Cytogenet. 1995;80(2):165–166
  39. Dahlenfors R, Lindahl L, Mark J. A fourth minor salivary gland mucoepidermoid carcinoma with 11q14–21 and 19p12 rearrangements. Hereditas. 1994;120(3):287–288
  40. El-Naggar AK, Lovell M, Killary AM, Clayman GL, Batsakis JG. A mucoepidermoid carcinoma of minor salivary gland with t(11;19)(q21;p13 1) as the only karyotypic abnormality. Cancer Genet Cytogenet. 1996;87(1):29–33
  41. Dahlenfors R, Wedell B, Rundrantz H, Mark J. Translocation(11;19)(q14–21;p12) in a parotid mucoepidermoid carcinoma of a child. Cancer Genet Cytogenet. 1995;79(2):188
  42. Johansson M, Mandahl N, Johansson L, Hambraeus G, Mitelman F, Heim S. Translocation 11;19 in a mucoepidermoid tumor of the lung. Cancer Genet Cytogenet. 1995;80(1):85–86
  43. Stenman G, Petursdottir V, Mellgren G, Mark J. A child with a t(11;19)(q14–21;p12) in a pulmonary mucoepidermoid carcinoma. Virchows Arch. 1998;433(6):579–581
  44. Roberts TG, Barry M, Skarin AT. Mucoepidermoid carcinoma of the lung with t(11:19)(q21:p13): a link to new biology. Clin Adv Hematol Oncol. 2003;1(8):486–487
  45. Vogelberg C, Mohr B, Fitze G, Friedrich K, Hahn G, Roesner D, et al. Mucoepidermoid carcinoma as an unusual cause for recurrent respiratory infections in a child. J Pediatr Hematol Oncol. 2005;27(3):162–165
  46. Serra A, Schackert HK, Mohr B, Weise A, Liehr T, Fitze G. t(11;19)(q21;p12∼p1311) and MECT1-MAML2 fusion transcript expression as a prognostic marker in infantile lung mucoepidermoid carcinoma. J Pediatr Surg. 2007;42(7):E23–E29
  47. Bullerdiek J, Haubrich J, Meyer K, Bartnitzke S. Translocation t(11;19)(q21;p13 1) as the sole chromosome abnormality in a cystadenolymphoma (Warthin’s tumor) of the parotid gland. Cancer Genet Cytogenet. 1988;35(1):129–132
  48. Mark J, Dahlenfors R, Stenman G, Nordquist A. A human adenolymphoma showing the chromosomal aberrations del (7)(p12p14–15) and t(11;19)(q21;p12–13). Anticancer Res. 1989;9(6):1565–1566
  49. Winnes M, Enlund F, Mark J, Stenman G. The MECT1-MAML2 gene fusion and benign Warthin’s tumor: is the MECT1-MAML2 gene fusion specific to mucuepidermoid carcinoma?. J Mol Diagn. 2006;8(3):394–395[author reply 395–6]
  50. Kaye FJ. Emerging biology of malignant salivary gland tumors offers new insights into the classification and treatment of mucoepidermoid cancer. Clin Cancer Res. 2006;12(13):3878–3881
  51. Fehr A, Röser K, Belge G, Löning T, Bullerdiek J. A closer look at Warthin tumors and the t(11;19). Cancer Genet Cytogenet. 2008;180(2):135–139
  52. Bell D, Luna MA, Weber RS, Kaye FJ, El-Naggar AK. CRTC1/MAML2 fusion transcript in Warthin’s tumor and mucoepidermoid carcinoma: evidence for a common genetic association. Genes Chromosomes Cancer. 2008;47(4):309–314
  53. Roser K, Fehr A, Belge G, Bullerdiek J, Schumacher U. Subtyping of carcinoma ex pleomorphic adenoma in salivary glands as mucoepidermoid carcinoma ex pleomorphic adenoma by a t(11;19) translocation assay (abstract). Oral Oncol Suppl. 2007;2(1):223
  54. Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms – part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007;60(2):145–159
  55. Gorunova L, Mertens F, Mandahl N, Jonsson N, Persson B, Heim S, et al. Cytogenetic heterogeneity in a clear cell hidradenoma of the skin. Cancer Genet Cytogenet. 1994;77(1):26–32
  56. Behboudi A, Winnes M, Gorunova L, van den Oord JJ, Mertens F, Enlund F, et al. Clear cell hidradenoma of the skin – a third tumor type with a t(11;19)-associated TORC1-MAML2 gene fusion. Genes Chromosomes Cancer. 2005;43(2):202–205
  57. Winnes M, Molne L, Suurkula M, Andren Y, Persson F, Enlund F, et al. Frequent fusion of the CRTC1 and MAML2 genes in clear cell variants of cutaneous hidradenomas. Genes Chromosomes Cancer. 2007;46(6):559–563
  58. Kazakov DV, Vanecek T, Belousova IE, Mukensnabl P, Kollertova D, Michal M. Skin-type hidradenoma of the breast parenchyma with t(11;19) translocation: hidradenoma of the breast. Am J Dermatopathol. 2007;29(5):457–461
  59. Hughes JH, Volk EE, Wilbur DC Cytopathology Resource Committee, College of American Pathologists. Pitfalls in salivary gland fine-needle aspiration cytology: lessons from the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology. Arch Pathol Lab Med. 2005;129(1):26–31
  60. Klijanienko J, Vielh P. Fine-needle sampling of salivary gland lesions IV. Review of 50 cases of mucoepidermoid carcinoma with histologic correlation. Diagn Cytopathol. 1997;17(2):92–98
  61. Brandwein M, Ivanov K, Wallace D, Hille JJ, Wang B, Fahmy A, et al. Salivary mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol. 2001;25:835–845
  62. Goode RK, Auclair PL, Ellis GL. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer. 1998;82(7):1217–1224
  63. Ellis GL, Auclair PL. Atlas of tumor pathology. Tumors of the salivary glands. Washington (DC): Armed Forces Institute of Pathology; 1996 [Series 3, Fascicle 17].
  64. McGurk M. Management of salivary gland cancer: clinically or pathologically based? Overview. In:  McGurk M,  Renehan A editor. Controversies in the management of salivary gland disease. Oxford: Oxford University Press; 2001;p. 155–161
  65. Spiro RH. Management of malignant tumors of the salivary glands. Oncology (Williston Park). 1998;12(5):671–680[discussion 683]
  66. Chen AM, Granchi PJ, Garcia J, Bucci MK, Fu KK, Eisele DW. Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 2007;67(4):982–987
  67. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006;24(17):2673–2678
  68. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7):2640–2653
  69. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006;244(2):176–184
  70. Sosman JA, Sozzi G, Pierotti MA. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res. 2007;13(2 Pt 2):764s–769s
  71. Bicknell R. The realisation of targeted antitumour therapy. Br J Cancer. 2005;92(Suppl. 1):S2–S5
  72. Gasparini P, Sozzi G, Pierotti MA. The role of chromosomal alterations in human cancer development. J Cell Biochem. 2007;102(2):320–331
  73. Fehr A, Roser K, Heidorn K, et al. A new type of MAML2 fusion in mucoepidermoid carcinoma. Genes Chromosomes Cancer. 2008;47(3):203–206
  74. Lannon CL, Sprensen PH. TV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin Cancer Biol. 2005;15(3):215–323
  75. Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med. 2005;25(2):363–378
  76. Gatenby RA, Vincent TL. An evolutionary model of carcinogenesis. Cancer Res. 2003;63(19):6212–6220
  77. Demichelis F, Rubin MA. TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. J Clin Pathol. 2007;60(11):1185–1186

PII: S1368-8375(08)00092-4

doi: 10.1016/j.oraloncology.2008.03.012

Oral Oncology
Volume 45, Issue 1 , Pages 2-9 , January 2009

Article Tools

* Image Usage & Resolution